Besides IMT, the ALK gene is subject to genomic rearrangements across a range of malignancies, including anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma, glioma, non–small cell lung cancer (NSCLC), colorectal, breast, ovarian, and esophageal cancer. This evidence concerns the gene ALK and non-small cell lung carcinoma.